Eslicarbazepine acetate is a Small Molecule owned by Bial – Portela & Ca, and is involved in 64 clinical trials, of which 61 were completed, 1 is ongoing, and 2 are planned.

Eslicarbazepine acetate is a voltage-gated sodium channel blocker. The drug preferably targets the inactivated state of the ion channel, preventing its return to the active state, and thereby reduces repetitive neuronal firing. Voltage-gated sodium channels play a key role in the initiation and propagation of action potentials in neurons and other electrically excitable cells such as myocytes and endocrine cells.

The revenue for Eslicarbazepine acetate is expected to reach a total of $1.3bn through 2033. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Eslicarbazepine acetate NPV Report.

Eslicarbazepine acetate is originated and owned by Bial – Portela & Ca. Sumitomo Pharma is the other company associated in development or marketing of Eslicarbazepine acetate.

Eslicarbazepine acetate Overview

Eslicarbazepine acetate (Exalief, Zebinix, Aptiom) is a carboxamide derivative, acts as an anti-epileptic agent. It is formulated as a form of tablets and suspension for oral route of administration. Apitom is indicated for the treatment of partial- onset seizures in patients  4 years of age and older. Zebinix is indicated as adjunctive therapy in adults, adolescents and children aged above 6 years with partial-onset seizures with or without secondary generalisation, Zebinix also used as a once-daily monotherapy to treat adults with newly-diagnosed partial-onset epilepsy.

Eslicarbazepine acetate (BIA 2-093) is under development for the treatment of partial-onset seizures. It was also under development for the treatment of fibromyalgia, postherpetic neuralgia, bipolar disorder, migraine and neuropathic pain.

Sumitomo Pharma Overview

Sumitomo Pharma, a subsidiary of Sumitomo Chemical Co Ltd develops, manufactures, sells, imports and exports pharmaceutical products. The company drugs are focused on major therapeutic areas which include regenerative diseases, oncology, psychiatry and neurology and infectious diseases. It also offers veterinary medicines for companion animals, primarily dogs, and cats, as well as for livestock such as cattle, swine, poultry, horses, and aquacultured fish. It also offers food additives, chemical product materials, food ingredients, and other products. Sumitomo Dainippon has research laboratories and manufacturing and distribution facilities in Japan. The company operates through subsidiaries and offices in North America, Europe, and Asia Pacific. Sumitomo Pharma is headquartered in Osaka, Japan.

The company reported revenues of (Yen) JPY560,035 million for the fiscal year ended March 2022 (FY2022), an increase of 8.5% over FY2021. In FY2022, the company’s operating margin was 10.8%, compared to an operating margin of 13.8% in FY2021. In FY2022, the company recorded a net margin of 10.1%, compared to a net margin of 10.9% in FY2021. The company reported revenues of JPY159,413 million for the second quarter ended September 2022, a decrease of 0.3% over the previous quarter.

Quick View – Eslicarbazepine acetate

Report Segments
  • Innovator (NME)
Drug Name
  • Eslicarbazepine acetate
Administration Pathway
  • Oral
Therapeutic Areas
  • Central Nervous System
Key Companies
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.